OI Therapy Raised BMD, Not Fracture Benefit - Report - MDSpire

OI Therapy Raised BMD, Not Fracture Benefit

Teriparatide followed by zoledronic acid increased bone mineral density but did not reduce fracture risk compared with standard care in adults with osteogenesis imperfecta.

  • By

  • Andrea Surnit

  • June 5, 2026

  • 7 min

Share

Clinical Report: OI Therapy Raised BMD, Not Fracture Benefit

Overview

The TOPaZ trial found that teriparatide followed by zoledronic acid improved bone mineral density (BMD) in adults with osteogenesis imperfecta but did not significantly reduce fracture incidence compared to standard care.

Background

Osteogenesis imperfecta (OI) is a genetic disorder characterized by fragile bones and increased fracture risk. Effective management of OI often focuses on improving bone density and reducing fracture rates. The role of pharmacologic therapies, such as teriparatide and zoledronic acid, in achieving these goals remains an important area of investigation.

Data Highlights

GroupImaging-confirmed FracturesBone Mineral Density (BMD)
Teriparatide + Zoledronic Acid65/176 (36.9%)Higher at lumbar spine and hip
Standard Care63/173 (36.4%)Lower than intervention group

Key Findings

Patient-reported fractures were more common than imaging-confirmed fractures, with no statistically significant difference between groups.

Clinical Implications

The findings suggest that while teriparatide and zoledronic acid can enhance bone mineral density in adults with OI, they may not effectively reduce fracture risk. Clinicians should consider these results when discussing treatment options with patients and managing expectations regarding fracture prevention.

Conclusion

The TOPaZ trial highlights the complexity of treating osteogenesis imperfecta, demonstrating improvements in bone density without corresponding reductions in fracture rates.

Related Resources & Content

  1. Teriparatide Plus Zoledronic Acid for Osteogenesis Imperfecta: A Randomized Clinical Trial | JAMA, 2026 -- JAMA Network
  2. Osteogenesis imperfecta - Symptoms, diagnosis and treatment | BMJ Best Practice US
  3. Knee Surgery, Sports Traumatology, Arthroscopy — Zoledronic acid demonstrates superior efficacy compared to ibandronic acid for managing symptomatic bone marrow lesions in the knee
  4. The Journal of Clinical Endocrinology & Metabolism — Bone Material Strength Index Is Low in Patients With Cushing's Syndrome Even After Long-term Remission
  5. Clinical Rheumatology — Lower odds of prevalent vertebral fractures with b/tsDMARD use among rheumatoid arthritis patients in clinical remission: a retrospective observational study
  6. The Journal of Clinical Endocrinology & Metabolism — Eldecalcitol Supplementation with Risedronate Mitigates Bone Density Loss Induced by Aromatase Inhibitors in Postmenopausal Women with Breast Cancer
  7. Teriparatide Plus Zoledronic Acid for Osteogenesis Imperfecta: A Randomized Clinical Trial | Clinical Pharmacy and Pharmacology | JAMA | JAMA Network
  8. Osteogenesis imperfecta - Symptoms, diagnosis and treatment | BMJ Best Practice US
  9. Guidelines – ERN BOND

Original Source(s)

OI Therapy Raised BMD, Not Fracture Benefit

  • by Andrea Surnit

  • June 5, 2026

Related Content

The dose-response relationship between physical activity and school scoliosis screening positive in children and adolescents: a preliminary cross-sectional study

AAE Revises Dental Trauma Guidance

Recommendations outline splinting, replantation timing, imaging, and long-term surveillance strategies for permanent tooth injuries.

The Aging Spine: Why Earlier Recognition and Individualized Care Matter More Than Ever

With an aging population, spine disorders are becoming increasingly common. Age-related spinal degeneration is nearly universal, but not all patients experience symptoms—and not all degeneration progresses the same way. 

  • May 27, 2026

  • 5 min